Sudden cardiac death in cardiac transplant recipients.

BACKGROUND: Sudden cardiac death (SCD) remains a significant cause of mortality in the general population. Its role in cardiac transplant patients-including its incidence, mechanism, potential risk factors, or influence on survival in this patient population-has not been well described. METHODS AND RESULTS: We undertook a retrospective analysis of the clinical and autopsy records of 257 patient deaths. SCD was analyzed in relation to severity and frequency of rejection episodes, clinical history of arrhythmias, coronary artery disease (CAD), hypertension, diabetes, left ventricular dysfunction, and clinical history of premorbid symptoms. A total of 25 patients were identified as having died of SCD, an incidence of 9.7%: 20% died < or = 12 months after transplantation, 80% died after > 12 months, and 20% died after > or = 60 months. Patient survival ranged from 2.5 to 138 months (mean, 45.7 months). The mean number of rejection episodes per patient was 2.6, most occurring within 12 months after transplantation. Echocardiography or multigated acquisition scan revealed an ejection fraction (EF) > or = 50% in 68% of patients; however, the presence of arrhythmias, primarily atrial, was evident in 68% of patients and was equally distributed between patients with EFs > or = 50% and EFs < 50%. CAD was present in 53% of patients (10 of 19) whose angiograms were available, and the appearance of CAD after transplantation was between 29 and 85 months (mean, 51.4 months). Of the 9 patients with normal cardiac catheterization studies, 6 with available autopsy reports had documented CAD. Autopsy data in 13 of 25 patients revealed CAD in 92% and rejection in 15% (International Society for Heart and Lung Transplantation grade > 3A). Of the deaths, 64% occurred within 3 months of the last endomyocardial biopsy, 96% had normal biopsies, and the only rejection was without hemodynamic compromise. CONCLUSIONS: SCD occurs relatively frequently in the cardiac transplant population, and CAD is present in most of the patients. Because the frequency of arrhythmias is relatively high in this group, more aggressive antiarrhythmic therapy may be beneficial for patients with allograft CAD in the prevention of SCD.

Transmyocardial laser revascularization.

Transmyocardial laser revascularization is a technique to create new vessels in underperfused areas of the ischemic heart. These vessels carry blood directly from the left ventricle of the heart into the myocardium. Clinical trials of this technique are currently underway.

Mechanical circulatory support in children.

Nine children (aged 1.2-15 years) have been treated with mechanical circulatory support devices at our institution. Indications for treatment were acute cardiac allograft rejection (n = 4), postcardiotomy cardiogenic shock (n = 4), and bridge to cardiac transplantation (n = 1). Eight patients required left ventricular support, and one required biventricular support. A BioMedicus centrifugal pump was used in eight patients, and a Hemopump intra-aortic axial flow device was used in one patient. In two patients, an intra-aortic balloon pump was in place at the time that circulatory support was instituted. Mechanical support time ranged from 2 to 139 h, and the average flow index was 2.31 l/min per m2. Three patients required hemodialysis during support, and one patient required re-exploration because of mediastinal hemorrhage. Recovery of native ventricular function was assessed by transthoracic or transesophageal echocardiography, and weaning from the device was achieved by gradually decreasing pump flow in increments of 0.1 to 0.5 l/min. Seven patients were successfully weaned from support. Two hospital deaths occurred after circulatory support had been discontinued: one patient died of respiratory failure and the other of gram-negative pneumonia and sepsis. The five surviving patients experienced no significant complications, and their hemodynamic indices were normal at the time of discharge. At a mean follow-up of 28.8 months, these patients are leading active unrestricted lives, with no long-term device-related sequelae. Based on this experience, mechanical circulatory support is feasible in children who experience profound circulatory failure from a variety of causes.

Hemopump left ventricular support in the peripartum cardiomyopathy patient.

The Hemopump temporary cardiac assist system underwent clinical trials within the United States from 1988 to 1991. Use of the device proved life-saving in providing left ventricular assistance for failing hearts. Presentation of a case study demonstrating the effects of Hemopump support is provided along with a detailed nursing care plan. A brief discussion of peripartum cardiomyopathy is also included.

Recovery of pulmonary function in patients undergoing extended left ventricular assistance.

Heart transplantation should follow the implantation of a left ventricular assist device (LVAD) only after optimal postoperative recovery of pulmonary function. We reviewed hospital records of 12 patients who underwent extended (greater than 30 days) left ventricular support before transplantation to determine the rate of return of pulmonary function. The mean cardiac index and pulmonary capillary wedge pressure returned to normal in all patients within three days after LVAD implantation. The mean pulmonary artery pressure and pulmonary vascular resistance decreased but did not return to normal. The mean central venous pressure remained elevated throughout the first month but decreased by the time of transplantation. Supplemental oxygen requirements and peak airway pressures improved, and ten of the 12 patients were extubated by the fifth postoperative day. Preoperative roentgenographic evidence of pulmonary edema was present in eight patients, and pulmonary hilar prominence was present in the remaining four patients. Roentgenographic resolution of the pulmonary edema occurred slowly, persisting for one week after surgery in seven of eight patients. Ten patients were able to exercise strenuously 30 days after surgery, and 11 were returned to excellent condition before undergoing heart transplantation. Although the hemodynamic status in these patients significantly improved shortly after LVAD implantation, optimal recovery of pulmonary function required several weeks. Therefore, we advocate delaying transplantation after LVAD implantation to allow optimal pulmonary recovery.

Thermo cardiosystems left ventricular assist device as a bridge to cardiac transplant.

In 1986, clinical trials were initiated with a left ventricular assist device capable of supporting individuals in end-stage heart disease for extended periods of time (longer than 14 days). While supported by this device, patients were hemodynamically stabilized for future transplant and were afforded an opportunity to improve their overall health status. At initiation of support these patients were in New York Heart Association class IV, and within approximately 2 weeks, improved to class I. Their nutritional status improved, they were able to exercise regularly, and they became the "healthiest" candidates for cardiac transplant. Nursing care of a patient requiring the HeartMate provides the critical care nurse with new challenges.

Quality of life in long-term survivors of the Hemopump left ventricular assist device.

The courses of 10 patients (nine men and one woman; mean age, 54 years) were reviewed to determine the long-term results of treatment with the Hemopump (Nimbus Medical, Inc., Rancho Cordova, CA) left ventricular assist device. Indications for treatment were postcardiotomy cardiogenic shock (n = 8) and acute cardiac allograft rejection (n = 2). Two of the patients with postcardiotomy shock required a bridge to transplantation. At follow-up (mean, 21 months), eight patients were alive: four were in New York Heart Association Functional Class I and four were in Class II. None had long-term adverse effects that were attributable to the site of insertion (e.g., limb ischemia or infected groin wounds). All the patients considered themselves independent in their daily activities, and most of the patients were able to exercise and pursue hobbies. The Hemopump appears to offer long-term survival with an acceptable quality of life to a population of patients whose survival would have been highly unlikely otherwise.

Extended support with a left ventricular assist device as a bridge to heart transplantation.

The Heartmate-1000IP, an intracorporeal, pneumatically activated, pulsatile left ventricular assist device (LVAD) with textured blood-contacting surfaces, is undergoing clinical evaluation as a bridge to heart transplantation (HTx). During a 3 year period (January 1988 to April 1991), the authors evaluated 12 patients who required extended LVAD support (greater than 30 days) while awaiting HTx. Duration of support ranged from 31 to 233 days (mean, 117 days). LVAD performance was excellent, with average pump flow indices of 2.5-3.5 L/min/m2. Long-term antithrombotic therapy consisted of dipyridamole and aspirin in all except one patient who received only low-molecular-weight dextran. After the initial recovery period, prothrombin and partial thromboplastin times returned to baseline levels. Plasma-free hemoglobin levels averaged less than 10 mg/dl. One patient is currently receiving support (91+ days); the 11 other patients underwent successful HTx, with follow-up ranging from 7 to 36 months. The authors' cumulative experience with this LVAD totals more than 1,506 days of support (greater than 4 years) without evidence of any thromboembolic episodes. These results suggest that this LVAD provides an effective bridge to HTx for extended periods.